BioSpace News Archive

Rapha Capital Management, LLC (https://raphacap.com), an investment management firm located in Miami, Florida, is pleased to announce that on February 17, 2021, its portfolio company, NexImmune, Inc. (“NexImmune”), c

Sparta Group has just announced that Assure Tech’s EcoTest® COVID-19 IgM/IgG Antibody Rapid Test and EcoTest® COVID-19 Antigen Rapid Test they planned to incorporate into their COVID-19 Safety System have been authorized by Health Canada for point-of-care use across the country.

Dental providers now have access to a powerful new tool to help identify a high-risk virus known to cause head and neck cancer.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, March 2, 2021 to discuss the Company’s financial results for the fiscal 2021 third quarter ended December 31, 2020,

It’s never easy to live with a compromised immune system. Often those who have a weakened immune system are already struggling with other things such as cancer or a transplant that require immunosuppressive medicine.

Locus Biosciences, a clinical-stage biotechnology company, announced today the completion of its Phase 1b clinical trial of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage (crPhage™) precision medicine product targeting Escherichia coli (E. coli) bacteria causing urinary tract infections (UTIs).

VLP BioTech, Inc., a private, preclinical biotechnology company, focused on designing epitope-based vaccines, announces the development of a therapeutic vaccine for the treatment of chronic HBV/HDV infections.

Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day

New Patent Significantly Bolsters Already Strong I.P. Portfolio and Enhances Company’s Ability to Maximize Return from Research Initiatives with New Product Launches

Reports of increased drug overdoses and drug overdose deaths during the COVID-19 pandemic are highlighting an increased need for innovative approaches to substance use disorder prevention and treatment.